Characteristics and risk factors of secondary bacterial infections in COVID-19 patients.
COVID-19
antibiotic
risk factor
secondary bacterial infections
Journal
Antimicrobial stewardship & healthcare epidemiology : ASHE
ISSN: 2732-494X
Titre abrégé: Antimicrob Steward Healthc Epidemiol
Pays: England
ID NLM: 9918266096106676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
05
2023
revised:
12
07
2023
accepted:
13
07
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
To describe the characteristics and find out risk factors of COVID-19 patients infected with different categories of bacteria. Case-control. We conducted a retrospective study including 129 COVID-19 patients admitted to a tertiary hospital between October 13, 2022 and December 31, 2022. Patients' data were collected from the hospital information system. Patients were classified as having or not having confirmed secondary bacterial infections, or gram-positive and gram-negative bacterial infections for analysis. Categories and sources of isolated bacteria, characteristics of the patients, and the risk factors for developing secondary bacterial infections were analyzed. Gram-negative bacteria accounted for the majority of secondary bacterial infections of the included patients. Critical type of COVID-19 (OR = 12.98, 95%CI 3.43∼49.18, Critical patients with invasive therapy and previous antibiotics use should be cautious with secondary bacterial infections. Third-generation cephalosporins and carbapenems should be used carefully because both are risk factors for gram-positive or gram-negative bacterial infections.
Identifiants
pubmed: 37771749
doi: 10.1017/ash.2023.425
pii: S2732494X23004254
pmc: PMC10523549
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e156Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
All authors report no conflicts of interest relevant to this article.
Références
Clin Microbiol Infect. 2021 Feb;27(2):228-235
pubmed: 33130270
Front Med (Lausanne). 2022 Jan 12;8:808391
pubmed: 35096895
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
mBio. 2015 Nov 10;6(6):e01346-15
pubmed: 26556272
BMC Pulm Med. 2023 Jan 20;23(1):30
pubmed: 36670381
J Antimicrob Chemother. 2021 Mar 12;76(4):1078-1084
pubmed: 33374002
Infect Immun. 2018 Nov 20;86(12):
pubmed: 30224553
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Clin Microbiol Infect. 2022 Apr;28(4):491-501
pubmed: 34843962
J Gerontol A Biol Sci Med Sci. 2022 Apr 1;77(4):e115-e123
pubmed: 34272847
J Antimicrob Chemother. 2023 Mar 2;78(3):840-849
pubmed: 36740939
J Infect. 2020 Mar;80(3):279-285
pubmed: 31682878
Cell Rep Med. 2021 Apr 20;2(4):100229
pubmed: 33748789
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Biochem Med (Zagreb). 2021 Oct 15;31(3):030501
pubmed: 34658642
Lancet Microbe. 2023 Mar;4(3):e179-e191
pubmed: 36736332
Infect Control Hosp Epidemiol. 2020 Aug;41(8):982-983
pubmed: 32279676
J Korean Med Sci. 2023 Jan 30;38(4):e37
pubmed: 36718563
J Microbiol Immunol Infect. 2022 Dec;55(6 Pt 1):985-992
pubmed: 36243668
Surg Infect (Larchmt). 2021 Jun;22(5):543-550
pubmed: 33112712
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038269
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
BMJ Open. 2019 Jul 30;9(7):e028576
pubmed: 31366651
Clin Infect Dis. 2019 Jul 18;69(3):388-396
pubmed: 30358811
Pneumonia (Nathan). 2021 Apr 25;13(1):5
pubmed: 33894790
Emerg Infect Dis. 2021 Apr;27(4):1234-1237
pubmed: 33565961
Eur J Med Res. 2023 Jan 21;28(1):43
pubmed: 36681833
Thorax. 2010 Mar;65(3):201-7
pubmed: 19825784